126 results about "ANXIETY COMPLEX" patented technology

The invention relates to an oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis, which is prepared by adopting the following raw materials of traditional Chinese medicines in parts by weight: 15+ / -3 of roasted astragalus root, 10+ / -2 of American ginseng, 10+ / -2 of white atractylodes rhizome, 10+ / -2 of tall gastrodia tuber, 10+ / -2 of medlar, 10+ / -2 of prepared rehmannia root, 10+ / -2 of white peony root, 10+ / -2 of radix salviae miltiorrhizae, 10+ / -2 of angelica, 10+ / -2 of rhizoma ligustici wallichii, 10+ / -2 of herba epimedii, 15+ / -3 of spine date seed, 10+ / -2 of tuckahoe, 10+ / -2 of rhizoma anemarrhenae, 10+ / -2 of rhizoma cyperi, 10+ / -2 of radix bupleuri, 10+ / -2 of TurmericRoot-tuber and 6+ / -1.2 of roasted licorice. The observation of clinical curative effect proves that the total effective rate of the invention for treating the anxiety neurosis is 92.2%; the total effective rate of the invention for treating the melancholia is 91.0%. The curative effect of the oral traditional Chinese medicine preparation is similar to the curative effect of the western medicines of buspirone for treating the anxiety neurosis and fluoxetine for treating the melancholia. Moreover, the traditional Chinese medicine preparation has no obvious toxic or side effect and can be taken for a long time. The preparation has small dose, easy release of the effective components of the medicine, quick absorption, full exertion of the medicine effect, convenient carrying and easy taking and is beneficial to large-scale production.

The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.

The invention discloses an application of a P2X2 receptor agonist or a P2X2 receptor opening agent in preparation of anti-depression or anti-anxiety drugs. According to the present invention, experiment research results confirm that: the P2X2 receptor agonist or the P2X2 receptor opening agent has an anti-depression and / or anti-anxiety effect, such that the P2X2 receptor agonist or the P2X2 receptor opening agent can be used for preparing anti-depression or anti-anxiety drugs, and can be adopted to screen prevention and treatment target points of anti-depression and / or anti-anxiety drugs and screen early stage pre-warning and clinical diagnostic reagents of depression and / or anxiety so as to provide broad application prospects.

This invention is directed to indolone derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and / or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and / or anxiety. This invention also provides a method of treating depression and / or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.

The invention relates to methods and compositions for promoting cognitive function and / or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.